{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:44:30Z","timestamp":1777765470188,"version":"3.51.4"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: CD93, an angiogenesis-related transmembrane glycoprotein, is transcriptomically downregulated in uterine corpus endometrial carcinoma, yet circulating protein levels have not been clinically evaluated. This study aimed to evaluate serum CD93 as a diagnostic biomarker for EC and to examine its association with clinicopathological parameters. Methods: In this single-center case\u2013control study, serum CD93 concentrations were measured by enzyme-linked immunosorbent assay in 46 patients with histologically confirmed primary EC and 35 controls with histologically verified benign gynecological pathology. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed. Results: Serum CD93 was significantly lower in EC patients than controls (median 4.55 [IQR 3.51\u20136.97] vs. 10.24 [7.18\u201312.14] ng\/mL; p &lt; 0.001). In multivariable analysis adjusted for age and body mass index, lower CD93 remained independently associated with EC (OR = 0.521; 95% CI 0.061\u20130.720; p &lt; 0.001). ROC analysis yielded an area under the curve of 0.845 (95% CI 0.759\u20130.921), with 82.6% sensitivity and 74.3% specificity at a cut-off of 7.338 ng\/mL. CD93 levels showed no significant association with histological subtype, grade, lymphovascular space invasion, nodal metastasis, or recurrence. Conclusions: Serum CD93 is significantly reduced in EC and demonstrates independent diagnostic performance, supporting its prospective validation as a non-invasive biomarker in larger multicenter cohorts.<\/jats:p>","DOI":"10.3390\/jcm15093409","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:01:18Z","timestamp":1777474878000},"page":"3409","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case\u2013Control Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0619-7111","authenticated-orcid":false,"given":"\u0130smail","family":"Ba\u011flar","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Health Sciences, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, 34865 Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3166-7129","authenticated-orcid":false,"given":"Fatih","family":"\u015eanl\u0131kan","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, University of Health Sciences, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, 34865 Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8099-8883","authenticated-orcid":false,"given":"Esra","family":"Keles","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, University of Health Sciences, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, 34865 Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5122-829X","authenticated-orcid":false,"given":"Sahra Sultan","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Health Sciences, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, 34865 Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-0911","authenticated-orcid":false,"given":"Cansu Ergen\u00e7","family":"\u00d6zda\u015f","sequence":"additional","affiliation":[{"name":"Management Department, Business School, Ankara Yildirim Beyazit University, 06010 Ankara, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeliz \u00c7e\u00e7en","family":"D\u00f6nmez","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Health Sciences, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, 34865 Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1347-8498","authenticated-orcid":false,"given":"Hafize","family":"Uzun","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, 34408 Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Boro\u0144, D., Zmarz\u0142y, N., Wierzbik-Stro\u0144ska, M., Rosi\u0144czuk, J., Mieszcza\u0144ski, P., and Grabarek, B.O. (2022). Recent multiomics approaches in endometrial cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031237"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12014-025-09528-6","article-title":"Present progress in biomarker discovery of endometrial cancer by multi-omics approaches","volume":"22","author":"An","year":"2025","journal-title":"Clin. Proteom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2022.10.024","article-title":"Molecular testing for endometrial cancer: An SGO clinical practice statement","volume":"168","author":"Walsh","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1111\/j.1742-4658.2005.05031.x","article-title":"The C-type lectin-like domain superfamily","volume":"272","author":"Zelensky","year":"2005","journal-title":"FEBS J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2021.05.006","article-title":"The C-type lectin CD93 controls endothelial cell migration via activation of the Rho family of small GTPases","volume":"99","author":"Barbera","year":"2021","journal-title":"Matrix Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI97459","article-title":"CD93 promotes \u03b21 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis","volume":"128","author":"Lugano","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.matbio.2017.08.003","article-title":"Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium","volume":"64","author":"Galvagni","year":"2017","journal-title":"Matrix Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.4049\/jimmunol.172.6.3406","article-title":"Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis","volume":"172","author":"Norsworthy","year":"2004","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/1354750X.2018.1443510","article-title":"Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model","volume":"23","author":"Park","year":"2018","journal-title":"Biomarkers"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cai, M., Zhou, X., Wang, S., Huang, X., Chen, W., Chen, Y., Huang, L., Yan, Y., Zhu, Y., and Ye, L. (2025). CD93 in health and disease: Bridging physiological functions and clinical applications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178617"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1158\/0008-5472.CAN-14-3636","article-title":"Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival","volume":"75","author":"Langenkamp","year":"2015","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/path.4072","article-title":"Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGF\u03b22 in vascular abnormalization","volume":"228","author":"Dieterich","year":"2012","journal-title":"J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.12998\/wjcc.v11.i4.738","article-title":"CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment","volume":"11","author":"Li","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jiang, Q., Kuai, J., Jiang, Z., Que, W., Wang, P., Huang, W., Ding, W., and Zhong, L. (2023). CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1158360"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yang, S., Bai, Z., Zhang, F., Cui, W., Bu, P., Bai, W., and Xi, Y. (2025). Expression and prognostic significance of CD93 in blood vessels in colorectal cancer: An immunohistochemical analysis of 134 cases. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03643-2"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eabc8922","DOI":"10.1126\/scitranslmed.abc8922","article-title":"Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy","volume":"13","author":"Sun","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tong, W., Wang, G., Zhu, L., Bai, Y., Liu, Z., Yang, L., Wu, H., Cui, T., and Zhang, Y. (2022). Pan-cancer analysis identified CD93 as a valuable biomarker for predicting patient prognosis and immunotherapy response. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.793445"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zheng, M., Ding, Q., and Liu, M. (2022). CD93 correlates with immune infiltration and impacts patient immunotherapy efficacy: A pan-cancer analysis. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.817965"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1111\/jog.14979","article-title":"Tumor diameter as a predictor of lymph node involvement in endometrioid type endometrial adenocarcinomas","volume":"47","author":"Kabaca","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e169830","DOI":"10.1172\/jci.insight.169830","article-title":"CD93 maintains endothelial barrier function and limits metastatic dissemination","volume":"9","author":"Vemuri","year":"2024","journal-title":"JCI Insight"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.str.2023.12.011","article-title":"Structural insight into CD93 recognition by IGFBP7","volume":"32","author":"Xu","year":"2024","journal-title":"Structure"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/jcp.25689","article-title":"CD93 as a potential target in neovascular age-related macular degeneration","volume":"232","author":"Tosi","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/14728222.2025.2500427","article-title":"Cellular role of CD93 and its potential as a future therapeutic target","volume":"29","author":"Orlandini","year":"2025","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373.","DOI":"10.1038\/nature12113"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.18632\/oncotarget.1887","article-title":"The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target","volume":"5","author":"Orlandini","year":"2014","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.18632\/oncotarget.7136","article-title":"CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration","volume":"7","author":"Galvagni","year":"2016","journal-title":"Oncotarget"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3409\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:24:21Z","timestamp":1777476261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15093409"],"URL":"https:\/\/doi.org\/10.3390\/jcm15093409","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}